Pro-Dex, Inc. Appoints Harold A. Hurwitz Chief Executive Officer

       Pro-Dex, Inc. Appoints Harold A. Hurwitz Chief Executive Officer

PR Newswire

IRVINE, Calif., Feb. 25, 2013

IRVINE, Calif., Feb. 25, 2013 /PRNewswire/ -- PRO-DEX, INC. (NasdaqCM: PDEX)
announced today that its Board of Directors voted unanimously to combine the
roles of Chief Executive Officer and Chief Financial Officer and appointed
Harold A. Hurwitz to the position of Chief Executive Officer effective
immediately. Mr. Hurwitz will retain his position as the Company's Chief
Financial Officer. He succeeds Michael J. Berthelot, who had served as the
Company's Chief Executive Officer since April 2012.

(Logo: http://photos.prnewswire.com/prnh/20111025/LA93174LOGO-c)

Mr. Hurwitz, 61, has served as the Company's Chief Financial Officer since
2010. From 2008 to 2010, Mr. Hurwitz was Vice President and Chief Financial
Officer for Interventional Spine Inc., a medical device company focused on
percutaneous systems for treatment of back pain. Prior to that, he was a
Principal Consultant with McDermott & Bull, a retained executive search firm,
where he specialized in serving the life science industry. From 1997 through
2004, Mr. Hurwitz was Vice President and Chief Financial Officer for Micro
Therapeutics, Inc., a developer and manufacturer of interventional
neurovascular medical devices, now part of Covidien plc. Mr. Hurwitz began
his career with Coopers & Lybrand, L.L.P., now part of PricewaterhouseCoopers
LLP, where he served for 22 years, leading its life science and high
technology practices in Orange County.

Nick Swenson, Chairman of the Company's Board of Directors, commented,
"Pro-Dex seeks to embrace the scale-enabled qualities of great small
companies, such as flexibility and the potential of any one employee to
understand the character, capability, and personality of any other company
employee. We believe these characteristics will help achieve an environment
that leads to improved freedom of information flow, a low requirement for
strictures and first-hand knowledge about individual productivity, all of
which should serve to increase Pro-Dex's ability to respond to customer needs,
solve problems and innovate."

"The board has confidence that Hal's thoughtful leadership style will bring
out the best in Pro-Dex. Hal is a veteran of the medical device industry and
his experience on the Pro-Dex senior leadership team gives him an in-depth
knowledge of Pro-Dex's business. I believe that V.P. level leaders at Pro-Dex
are also accomplished veterans in their respective domains. They appear eager
to exercise their talents. The leadership of Pro-Dex is in very capable
hands."

"The board's consolidation of the CEO and CFO roles will result in a reduced
cost footprint. While in the first year this benefit will be offset by an
approximate $165,000 one-time change of control payment to Mr. Berthelot (as
required under Mr. Berthelot's change of control agreement that was approved
by Pro-Dex's previously constituted Board of Directors), savings after the
first year will be approximately $260,000 annually, which is nearly 3% of
Pro-Dex's most recent publicly reported shareholders' equity at December 31,
2012. In addition, the option to purchase 200,000 shares of Pro-Dex common
stock previously issued to Mr. Berthelot by the previously constituted Board
of Directors will be extinguished at no cost to the Company."

Mr. Swenson continued, "We thank Mike Berthelot for his three years of service
as a member of our Board of Directors and his ten months of service as Chief
Executive Officer. During that short period, he acted decisively to implement
thoughtful and much needed operational change and to institute foundational
practices that will surely outlive his tenure. We wish him well in his future
pursuits."

"I am privileged to be able to work with Pro-Dex's dedicated management team
and associates," said Mr. Hurwitz. "Together with the guidance of our
recently reconstituted Board, and in partnership with our customers, I look
forward to building upon the company's achievements for the benefit of all of
its stakeholders."

Pro-Dex, Inc., with operations in California and Oregon, specializes in the
design, development and manufacture of powered rotary drive surgical and
dental instruments used primarily in the orthopedic, spine, maxocranial facial
and dental markets. Its OMS division designs and manufactures embedded motion
control systems serving the medical, dental, semi-conductor and scientific
research markets. Pro-Dex's products are found in hospitals, dental offices,
medical engineering labs, scientific research facilities and high tech
manufacturing operations around the world. For more information, visit the
Company's website at www.pro-dex.com.

Statements herein concerning the Company's plans, growth and strategies may
include 'forward-looking statements' within the context of the federal
securities laws. Statements regarding the Company's future events,
developments and future performance, as well as management's expectations,
beliefs, plans, estimates or projections relating to the future, are
forward-looking statements within the meaning of these laws. The Company's
actual results may differ materially from those suggested as a result of
various factors. Interested parties should refer to the disclosure concerning
the operational and business concerns of the Company set forth in the
Company's filings with the Securities and Exchange Commission.

SOURCE Pro-Dex, Inc.

Website: http://www.pro-dex.com
Contact: Nick Swenson, Chairman of the Board, +1-949-769-3200
 
Press spacebar to pause and continue. Press esc to stop.